SCHEMBL4861645

SCHEMBL4861645

C=C(C(N)=O)C(CC)NC

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.35
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127680 0.86
SCHEMBL29286895 0.81 TDP1 (0.33) TDP1KDM4E
SCHEMBL4861560 0.81 TDP1 (0.33) TDP1KDM4E
SCHEMBL6364868 0.80 TGFBR1 (0.31)
SCHEMBL11670289 0.79 TDP1 (0.32) TDP1KDM4E
SCHEMBL7132286 0.78 TDP1 (0.31) TDP1KDM4E
SCHEMBL4774722 0.77
SCHEMBL12836545 0.77
SCHEMBL20932853 0.77
SCHEMBL16782434 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250235390-A1 Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2025-07-24 US claimed
EP-4419062-A1 COMPOSITION AND PROCESS FOR TREATING A DISORDER IN THE ORAL CAVITY OF A MAMMAL Solventum Intellectual Properties Company (US) 2024-08-28 EP claimed
US-11766386-B2 Medical composition containing guanidinyl-containing polymer(s) and carrageenane(s) 3M INNOVATIVE PROPERTIES COMPANY (US) 2023-09-26 US claimed
WO-2023067453-A1 COMPOSITION AND PROCESS FOR TREATING A DISORDER IN THE ORAL CAVITY OF A MAMMAL 3M INNOVATIVE PROPERTIES COMPANY (US) 2023-04-27 WO claimed
EP-0118327-B1 CATIONIC LATICES FROM CONJUGATED DIENES RHONE-POULENC CHIMIE (FR) 1987-04-22 EP claimed
US-12630582-B2 Method for biomaterial purification and kits thereof Life Technologies Corporation (US) 2026-05-19 US disclosed
US-20250235390-A1 Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2025-07-24 US disclosed
EP-3534867-B1 MEDICAL COMPOSITION CONTAINING GUANIDINYL-CONTAINING POLYMER(S) AND CARRAGEENANE(S) SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2025-06-04 EP disclosed
EP-3534866-B1 METHOD OF DENTAL RETRACTION WITH COMPOSITION WITH GUANIDINYL-CONTAINING POLYMER SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) 2025-05-28 EP disclosed
US-20250082440-A1 Composition for Isolating Tissue SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2025-03-13 US disclosed
CN-115135307-B Cell delivery vehicle 株式会社ITO 2024-11-22 CN disclosed
EP-4419062-A1 COMPOSITION AND PROCESS FOR TREATING A DISORDER IN THE ORAL CAVITY OF A MAMMAL Solventum Intellectual Properties Company (US) 2024-08-28 EP disclosed
EP-1616957-A1 VECTOR Japan as represented by president of National Cardiovascular Center (JP) 2006-01-18 EP disclosed
US-20050235870-A1 2-ethyl-1,3-hexanediol, acetylene glycol surfactant and/or penetrating organic solvent, and humectant; ink jet printing; highly stably ejected and evenly printed on recording media; clogged nozzle problem prevented SEIKO EPSON CORPORATION 2005-10-27 US disclosed
CN-1642998-A Basic polymers obtained by hydrogenation STOCKHAUSEN CHEM FAB GMBH (DE) 2005-07-20 CN disclosed
US-6877851-B2 Ink set for ink jet recording, ink jet recording process, and recorded matter SEIKO EPSON CORPORATION (JP) 2005-04-12 US disclosed
US-20040239738-A1 Ink set for ink jet recording, ink jet recording process, and recorded matter SEIKO EPSON CORPORATION 2004-12-02 US disclosed
EP-0315718-A2 Aqueous dispersion of cationic ethylenic copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1989-05-17 EP disclosed
EP-0293087-A1 Production of electrically conductive ethylene copolymer moldings SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-11-30 EP disclosed
EP-0269293-A2 Composition of a dyeable poly-alpha-olefin and a copolymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630582-B2 Method for biomaterial purification and kits thereof CD68, FIBP, BMP2 TDP1 661/4885KDM4E 3845/4885
US-11766386-B2 Medical composition containing guanidinyl-containing polymer(s) and carrageenane(s) GANC, GMPS, MGAM TDP1 2728/4885KDM4E 588/4885
US-20250235390-A1 Composition and Process for Treating a Disorder in the Oral Cavity of a Mammal GSDMD, PIGS, GANC TDP1 1508/4885KDM4E 3077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.